Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.350 +0.070 (+3.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets
Vistagen Therapeutics Inc (NASDAQ: VTGN) released topline results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
From Vistagen
Via Business Wire
VistaGen's New Preclinical Depression Treatment Study: Itruvone Nasal Spray Limits Systemic Exposure, Shows Promise
Vistagen Inc (NASDAQ: VTGN) revealed a new mechanism of action data from a preclinical tissue distribution  
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
Via Investor Brand Network
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
Via Investor Brand Network
Earnings Scheduled For June 28, 2023
Companies Reporting Before The Bell • General Mills (NYSE:GIS) is estimated to report quarterly earnings at $1.07 per share on revenue of $5.17 billion. 
Via Benzinga
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Eyes Advancement of Itruvone into Phase 2B Development
Via Investor Brand Network
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
From Vistagen
Via Business Wire
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Upcoming Maxim Group Healthcare Virtual Conference
Via Investor Brand Network
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
From Vistagen
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) PH80 Nasal Spray to Receive EPO Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH80 Exploratory Phase 2A Study
Via Investor Brand Network
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
Vistagen's Nasal Spray Shows Efficacy In Menopausal Hot Flashes
Vistagen Therapeutics Inc (NASDAQ: VTGN) announced that PH80, one of the Company's five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an... 
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Participate in Upcoming Jefferies Global Healthcare Conference
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
From Vistagen
Via Business Wire
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
From Vistagen
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.